<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069145</url>
  </required_header>
  <id_info>
    <org_study_id>54F28-004</org_study_id>
    <nct_id>NCT02069145</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer</brief_title>
  <official_title>A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoMed Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mereo BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and&#xD;
      PK of OMP-54F28 when combined with sorafenib. OMP-54F28 will be administered IV on Day 1 of&#xD;
      each 21-day cycle. The planned dose levels of OMP-54F28 are 5 and 10 mg/kg. Depending on&#xD;
      safety in this study, additional lower or intermediate dose levels may be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depending on emerging safety data from the Phase 1a study 54F28-001 with continuing dose&#xD;
      escalation, additional higher dose levels of OMP-54F28 may be evaluated in this study.&#xD;
      Alternative dosing schedules of OMP-54F28 may be explored based on emerging nonclinical and&#xD;
      clinical data for safety, PD, PK and efficacy. The starting dose for a new dosing schedule&#xD;
      will be chosen to result in an AUC equivalent to the highest dose level that cleared on the&#xD;
      previously studied dosing schedule. No dose escalation of OMP-54F28 will be allowed within a&#xD;
      dose cohort. Sorafenib 400 mg will be given orally twice daily (PO BID). Sorafenib dosing&#xD;
      schedules with a total daily dose &lt;800 mg (e.g. Sorafenib 400 mg once daily) may be evaluated&#xD;
      in this study depending on emerging safety data from this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of OMP-54F28 in combination with sorafenib in patients with hepatocellular cancer</measure>
    <time_frame>Subjects will be treated and observed for DLT through the end of the first cycle (from Day 0 - 21)</time_frame>
    <description>The maximum tolerated dose (MTD) will be determined in patients treated with OMP-54F28 in combination with sorafenib in patients with hepatocellular cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of OMP-54F28 and sorafenib when administered in combination to patients with hepatocellular cancer</measure>
    <time_frame>OMP-54F28 will be administered IV on Day 1 of each 21 day cycle. Plasma sample for Parmacokinetics (PK) analysis to be obtained at various time points, 30 minutes after end of OMP-54F28 infusion and before sorafenib treatment</time_frame>
    <description>Apparent half life, AUC, clearance, volume of distribution</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hepatocellular Cancer</condition>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Drug: OMP-54F28, with Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMP-54F28 with Sorafenib</intervention_name>
    <arm_group_label>Drug: OMP-54F28, with Sorafenib</arm_group_label>
    <other_name>OMP-54F28</other_name>
    <other_name>Sorafenib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Histologically documented hepatocellular carcinoma&#xD;
&#xD;
          -  Locally advanced or metastatic disease&#xD;
&#xD;
          -  Availability of FFPE tumor tissue, either archival or obtained at study entry through&#xD;
             fresh biopsy&#xD;
&#xD;
             o Tumor tissue from fine needle aspiration is not acceptable.&#xD;
&#xD;
          -  ECOG performance status of 0 or 1 (see Appendix C)&#xD;
&#xD;
          -  All acute treatment-related toxicity from prior therapy must have resolved to Grade ≤&#xD;
             1 prior to study entry&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  Child-Pugh Classification A (see Appendix D)&#xD;
&#xD;
          -  Evaluable or measurable disease per RECIST v1.1&#xD;
&#xD;
          -  For women of childbearing potential and men with partners of childbearing potential,&#xD;
             agreement to use two effective forms of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to take oral medications&#xD;
&#xD;
          -  Prior systemic therapy for locally advanced or metastatic hepatocellular cancer&#xD;
&#xD;
          -  Prior adjuvant therapy with sorafenib or another Raf/VEGF inhibitor&#xD;
&#xD;
          -  Prior history of allografts, including, but not limited to, liver and bone marrow&#xD;
             transplants&#xD;
&#xD;
          -  Esophageal or gastric variceal bleeding within last 3 months&#xD;
&#xD;
          -  Risk for varices, based on known history of esophageal or gastric varices, evidence of&#xD;
             hepatic cirrhosis and/or portal hypertension including biopsy-proven cirrhosis,&#xD;
             hypersplenism, or radiographic findings of varices&#xD;
&#xD;
          -  Clinically evident ascites&#xD;
&#xD;
          -  Evidence of encephalopathy within last 3 months&#xD;
&#xD;
          -  Treatment with inducers of cytochrome P450 3A4 (CYP3A4) within 7 days prior to first&#xD;
             dose of study treatment&#xD;
&#xD;
          -  Treatment with interferon within 4 weeks prior to first dose of study treatment&#xD;
&#xD;
          -  Treatment with any anti-cancer therapy, including radiotherapy, chemotherapy, biologic&#xD;
             therapy, or herbal therapy within 3 weeks or 5 half-lives (for systemic agents),&#xD;
             whichever is shorter&#xD;
&#xD;
          -  Known hypersensitivity to any component of study treatments that resulted in drug&#xD;
             discontinuation&#xD;
&#xD;
          -  Uncontrolled seizure disorder or active neurologic disease&#xD;
&#xD;
          -  Untreated brain metastases&#xD;
&#xD;
          -  Leptomeningeal disease as a manifestation of cancer&#xD;
&#xD;
          -  Active infection requiring antibiotics&#xD;
&#xD;
          -  Bisphosphonate therapy for symptomatic hypercalcemia&#xD;
&#xD;
          -  Significant intercurrent illness including, but not limited to, unstable angina&#xD;
             pectoris, and cardiac arrhythmia, or psychiatric illness/social situation that would&#xD;
             limit compliance with study requirements&#xD;
&#xD;
          -  Pregnancy, lactation, or breastfeeding&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Active Hepatitis B infection in the absence of adequate antiviral therapy&#xD;
&#xD;
          -  Uncontrolled hypertension, defined as systolic blood pressure &gt;140 mm Hg or diastolic&#xD;
             blood pressure &gt;90 mm Hg, despite medical management&#xD;
&#xD;
          -  Pulmonary hemorrhage of Grade ≥2 within 28 days prior to first dose of study treatment&#xD;
&#xD;
          -  Any other hemorrhage or bleeding of Grade ≥3 within 28 days prior to first dose of&#xD;
             study treatment&#xD;
&#xD;
          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of&#xD;
             therapeutic anticoagulation)&#xD;
&#xD;
          -  Concurrent use of therapeutic warfarin&#xD;
&#xD;
          -  New York Heart Association Classification III or IV (see Appendix F)&#xD;
&#xD;
          -  Congenital long QT syndrome&#xD;
&#xD;
          -  Known clinically significant gastrointestinal disease including, but not limited to,&#xD;
             inflammatory bowel disease&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to the first dose of study treatment or anticipation of need for major surgical&#xD;
             procedure during the course of the study&#xD;
&#xD;
          -  Osteoporosis based on a T-score of &lt;-2.5 at the left or right total hip, left or right&#xD;
             femoral neck or lumbar spine (L1-L4) as determined by DEXA scan&#xD;
&#xD;
          -  Bone metastases and one of the following:&#xD;
&#xD;
               -  Prior history of a pathologic fracture&#xD;
&#xD;
               -  Lytic lesion requiring an impending orthopedic intervention&#xD;
&#xD;
               -  Lack of treatment with a bisphosphonate or denosumab&#xD;
&#xD;
          -  Treatment with a thiazolidinedione PPAR gamma inhibitor; e.g. Actos® (pioglitazone)&#xD;
             and Avandia® (rosiglitzone)&#xD;
&#xD;
          -  Active treatment with an oral or IV glucocortocoid for ≥4 weeks at a daily dose&#xD;
             equivalent to or greater than 7.5 mg of oral prednisone&#xD;
&#xD;
          -  Fasting β-CTX of &gt;1000 pg/mL&#xD;
&#xD;
          -  Metabolic bone disease, such as hyperparathyroidism, Paget's disease or osteomalacia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachussetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 18, 2014</study_first_submitted>
  <study_first_submitted_qc>February 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2014</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Cancer</keyword>
  <keyword>Liver Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Immunoglobulin Fc Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

